Patents by Inventor Signe Eskildsen Larsen

Signe Eskildsen Larsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alpha-amylase variants and polynucleotides encoding same
    Patent number: 9334485
    Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: May 10, 2016
    Assignee: Novozymes A/S
    Inventors: Carsten Andersen, Signe Eskildsen Larsen, Esben Peter Friis, Peter Kamp Hansen, Henrik Friis Madsen, Anders Viksoe Nielsen, Pernille Ollendorf Micheelsen
  • Process for Hydrolysis of Starch
    Publication number: 20160122442
    Abstract: The present invention relates to a process for enzymatic hydrolysis of granular starch into a soluble starch hydrolysate at a temperature below or just above the initial gelatinization temperature of said granular starch.
    Type: Application
    Filed: April 10, 2014
    Publication date: May 5, 2016
    Applicant: Novozymes A/S
    Inventors: Carsten Andersen, Paria Saunders, Signe Eskildsen Larsen, Scott R. McLaughlin, Chee Leong Soong
  • Cleaning compositions comprising amylase variants reference to a sequence listing
    Patent number: 9284544
    Abstract: The present invention relates to cleaning compositions comprising variants of an alpha-amylase and methods of treating surfaces such as textiles with aqueous liquor comprising such compositions, especially at low temperatures.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: March 15, 2016
    Assignee: The Procter & Gamble Company
    Inventors: Michelle Jackson, Philip Frank Souter, Lindsay Suzanne Bewick, Svend Kaasgaard, Jens Oebro, Signe Eskildsen Larsen, Allan Svendsen, Annette Helle Johansen, Michael Skjoet, Carsten Andersen, Lars Beier, Esben Peter Friis, Miguel Duarte Guilherme Pereira Toscano, Mads Bjoernvad, Frank Winther Rasmussen, Liv Spaangner Christiansen
  • Lipase Variants for Pharmaceutical Use
    Publication number: 20150209414
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Application
    Filed: April 6, 2015
    Publication date: July 30, 2015
    Inventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • Lipase variants for pharmaceutical use
    Patent number: 9029115
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, and are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: May 12, 2015
    Assignees: Novozymes A/S, Novozymes Inc
    Inventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • Alpha-Amylase Variants and Polynucleotides Encoding Same
    Publication number: 20140234906
    Abstract: The present invention relates to alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: October 17, 2012
    Publication date: August 21, 2014
    Inventors: Carsten Andersen, Signe Eskildsen Larsen, Esben Peter Friis, Peter Kamp Hansen, Henrik Friis Madsen, Anders Viksoe Nielsen, Pernille Ollendorf Micheelsen
  • Method for Screening Alpha-Amylases
    Publication number: 20140206026
    Abstract: The present invention relates to variants of a parent alpha-amylase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: June 29, 2012
    Publication date: July 24, 2014
    Applicant: Novozymes A/S
    Inventors: Svend Kaasgaard, Signe Eskildsen Larsen, Jens Oebro, Lars Beier, Connie Pontoppidan, Iben Damager, Carsten Andersen, Allan Svendsen
  • ALPHA-AMYLASE VARIANTS
    Publication number: 20140141489
    Abstract: The present invention relates to variants of a parent alpha-amylase. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Application
    Filed: June 29, 2012
    Publication date: May 22, 2014
    Inventors: Svend Kaasgaard, Jens Oebro, Signe Eskildsen Larsen, Allan Svendsen, Annette Helle Johansen, Michael Skjoet, Carsten Andersen, Lars Beier, Esben Peter Friis, Miguel Duarte Guilherme Pereira Toscano, Mads Bjoernvad, Frank Winther Rasmussen, Liv Spaanger Christiansen
  • Protease variants for pharmaceutical use
    Patent number: 8455235
    Abstract: The invention relates to novel variants of a protease derived from Nocardiopsis sp. (SEQ ID NO: 1) and closely related proteases, as well as their pharmaceutical use. The variants show improved performance in the treatment of pancreatic exocrine insufficiency (PEI). The variants may be combined with a lipase and/or an amylase. Other examples of medical indications are: Treatment of digestive disorders, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: June 4, 2013
    Assignees: Novozymes A/S, Solvay Pharmaceuticals, GmbH
    Inventors: Allan Svendsen, Lars Beier, Signe Eskildsen Larsen, Thomas Lenhard, Tanja Maria Rosenkilde Kjaer, Peter Colin Gregory
  • CLEANING COMPOSITIONS COMPRISING AMYLASE VARIANTS REFERENCE TO A SEQUENCE LISTING
    Publication number: 20130000055
    Abstract: The present invention relates to cleaning compositions comprising variants of an alpha-amylase and methods of treating surfaces such as textiles with aqueous liquor comprising such compositions, especially at low temperatures.
    Type: Application
    Filed: June 29, 2012
    Publication date: January 3, 2013
    Inventors: Michelle Jackson, Philip Frank Souter, Lindsay Suzanne Bewick, Svend Kaasgaard, Jens Oebro, Signe Eskildsen Larsen, Allan Svendsen, Annette Helle Johansen, Michael Skjoet, Carsten Andersen, Lars Beier, Esben Peter Friis, Miguel Duarte Guilherme Pereira Toscano, Mads Bjoernvad, Frank Winther Rasmussen, Liv Spaangner Christiansen
  • Lipase Variants for Pharmaceutical Use
    Publication number: 20120308543
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Application
    Filed: August 16, 2012
    Publication date: December 6, 2012
    Applicants: NOVOZYMES, INC., NOVOZYMES A/S
    Inventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • Alpha-Amylase Variants and Polynucleotides Encoding Same
    Publication number: 20120282658
    Abstract: The present invention relates to variants of a parent alpha-amylase. The present invention also relates to polynucleotides encoding the variants and to nucleic acid constructs, vectors, and host cells comprising the polynucleotides, and methods of using the variant enzymes.
    Type: Application
    Filed: January 4, 2011
    Publication date: November 8, 2012
    Applicants: NOVOZYMES NORTH AMERICA, INC., NOVOZYMES A/S
    Inventors: Carsten Andersen, Randall Deinhammer, Thomas Agersten Poulsen, Miguel Duarte Toscano, Peter Kamp Hansen, Henrik Friis-Madsen, Anders Viksoe-Nielsen, Signe Eskildsen Larsen, Lars L.H. Christensen
  • Lipase variants for pharmaceutical use
    Patent number: 8273348
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: September 25, 2012
    Assignees: Novozymes A/S, Novozymes Inc.
    Inventors: Allan Svendsen, Michael Skjoet, Debbie Yaver, Lars Lehmann Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory
  • CLEANING COMPOSITION COMPRISING AMYLASE VARIANTS WITH HIGH STABILITY IN THE PRESENCE OF A CHELATING AGENT
    Publication number: 20110212876
    Abstract: The present invention relates to cleaning compositions comprising variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme and cleaning processes comprising such compositions.
    Type: Application
    Filed: February 10, 2011
    Publication date: September 1, 2011
    Inventors: Michelle MEEK, Philip Frank Souter, Lindsay Suzanne Bewick, Allan Svendsen, Annette Helle Johansen, Mads Eskelund Bjoernvad, Frank Winther Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • Variants And Compositions Comprising Variants With High Stability In Presence Of A Chelating Agent
    Publication number: 20110195481
    Abstract: The present invention relates to variants of an alpha-amylase having improved stability to chelating agents relative to its parent enzyme, compositions comprising the variants, nucleic acids encoding the variants, methods of producing the variants, and methods for using the variants.
    Type: Application
    Filed: February 10, 2011
    Publication date: August 11, 2011
    Applicant: Novozymes A/S
    Inventors: Allan Svendsen, Annette Helle Johansen, Mads Bjoernvad, Frank W. Rasmussen, Michael Skjoet, Signe Eskildsen Larsen, Jens Oebro, Svend Kaasgaard, Lars Beier
  • Protease Variants for Pharmaceutical Use
    Publication number: 20100322915
    Abstract: The invention relates to novel variants of a protease derived from Nocardiopsis sp. (SEQ ID NO: 1) and closely related proteases, as well as their pharmaceutical use. The variants show improved performance in the treatment of pancreatic exocrine insufficiency (PEI). The variants may be combined with a lipase and/or an amylase. Other examples of medical indications are: Treatment of digestive disorders, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.
    Type: Application
    Filed: December 2, 2008
    Publication date: December 23, 2010
    Applicants: Novozymes A/S, Solvay Pharmaceuticals, GmbH
    Inventors: Allan Svendsen, Lars Beier, Signe Eskildsen Larsen, Thomas Lenhard, Tanja Maria Rosenkilde Kjaer, Peter Colin Gregory
  • Lipase Variants for Pharmaceutical Use
    Publication number: 20100034797
    Abstract: The pharmaceutical use of lipases related to the Thermomyces lanuginosus (Humicola lanuginosa) lipase comprising amino acids 1-269 of SEQ ID NO: 2, optionally in combination with a protease and/or an amylase. Examples of medical indications are: Treatment of digestive disorders, pancreatic exocrine insufficiency (PEI), pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II. The lipases of the invention have, e.g., an improved digestion performance in vitro, an improved activity at a pH in the neutral range, an improved stability at low pH, an are stable against protease-degradation, and/or are stable in the presence of pepsin and bile salts. The invention also relates to methods of determining digestion performance in vitro of lipases, as well as to certain novel variants of the lipase of T. lanuginosus.
    Type: Application
    Filed: December 12, 2007
    Publication date: February 11, 2010
    Applicants: Novozymes A/S, Novozymes, Inc., Solvay Pharmaceuticals GmbH
    Inventors: Allan Svendsen, Michael Skjoet, Deborah Yaver, Lars Lehman Hylling Christensen, Signe Eskildsen Larsen, Nina Lundin, Michael Lamsa, Peter Colin Gregory